Skip to content

Artificial Intelligence Aid Systems in Colorectal Adenoma Detection

Usefulness of the Endo-AID Artificial Intelligence System in the Detection of Colorectal Adenomas. a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04945044
Acronym
INTELAID
Enrollment
370
Registered
2021-06-30
Start date
2021-11-15
Completion date
2022-01-31
Last updated
2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma Detection Rate

Brief summary

The main purpose of the study to evaluate the usefulness of the Endo-AID artificial intelligence system in the detection of colorectal adenomas in consecutive patients for outpatient colonoscopy. The secondary aims were: * To evaluate the benefit of Endo-AID in adenoma detection rate by comparing endoscopists with high and low adenoma detection rate. * To evaluate serrated detection rate, advanced adenoma detection rate, adenoma detection rate according to the size (\<= 5mm, 6-9mm,\> = 10mm) and number of adenomas by colonoscopy. Stratification by location and morphology.

Detailed description

Priority guidelines have been established regarding IA applied to gastrointestinal endoscopy. Regarding the priority uses for their development, there are applications that improve vision, placing computer-assisted lesion detection (CADe) as one of the most necessary priorities, given the importance of colorectal cancer screening (CRC) and post-polypectomy surveillance. The evaluation of these systems in different clinical practices and patient groups has been recommend. In this regard, studies in the western population are limited and have been carried out by expert endoscopists. It has not been evaluated in endoscopists with different adenoma detection rates. In addition, there are no studies with the recent CADe Endo-AID system (Olympus Corp. Tokyo). The main purpose of the study to evaluate the usefulness of the Endo-AID artificial intelligence system in the detection of colorectal adenomas in consecutive patients for outpatient colonoscopy. In addition, the benefit of the CADe system will be assessed according to the endoscopist ADR. A randomized controlled trial will be carried out in consecutive outpatients meeting the inclusion criteria and none of the exclusion criteria. Patients with be randomized to one of the four groups: CADe system and high ADR endoscopist; CADe system and low ADR endoscopist; Control and high ADR endoscopist; Control and low ADR endoscopist. For the sample size calculation a 14.4 of difference in favor of the CADe system was considered. Taking onto account an alpha error of 0.05 in a unilateral contrast, a power of 80% and a loss of 10%, 165 patients per group would be required.

Interventions

DEVICEComputed adenoma detection system (CADe)

This is a computed system that helps the endoscopist to increase the detection of colorectal polyps

BEHAVIORALControl group (regular colonoscopy)

It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)

Sponsors

Hospital Universitario de Canarias
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years. * Patients referred for outpatient colonoscopy

Exclusion criteria

* Colonic resection * Taking anticoagulants or antiagregants that contraindicate the performance of therapy * Patients with a recent colonoscopy (\<6 months) of good quality (e.g. cited for endoscopic therapy) * Inflammatory bowel disease * Patients with incomplete colonoscopy * Patients with inadequate preparation using the Boston Colonic Preparation Scale (BBPS). A cleaning quality of less than 2 points in any of the 3 colonic sections will be considered inadequate. * Patients with polyposis syndromes * Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Adenoma detection rate[Time frame: 1 years][Designated as safety issue: No]Number of colonoscopies with colorectal adenoma/Number of total colonoscopies

Secondary

MeasureTime frameDescription
Serrated detection rate[Time Frame: 1 years][Designated as safety issue: No]Number of colonoscopies with serrated adenoma/Number of total colonoscopies
Advanced adenoma detection rate[Time Frame: 1 years][Designated as safety issue: No]Number of colonoscopies with advanced adenoma/Number of total colonoscopies

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026